Morgan Stanley Initiates Coverage of Genmab, Assigns Equalweight Rating

Morgan Stanley has announced it will now cover Genmab A/S (ticker: GMB), giving the Danish biopharmaceutical company an equalweight rating. The brokerage cited Genmab’s robust drug pipeline and recent clinical milestones as the primary reasons for the rating, noting that the firm’s outlook remains positive amid a competitive oncology landscape.

The announcement comes as global markets are holding steady. Major equity indices are trading near recent highs, while commodities remain largely unchanged: gold is priced at $4,121.89, silver at $57.47, WTI crude at $99.45, Brent at $110.53, copper at $6.58, aluminium at $3,009.55, and natural gas at $3.01. These levels reflect a cautious but optimistic market sentiment as investors weigh corporate earnings and macroeconomic data.